Cargando…
Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study
BACKGROUND: Macular edema is found in more than half of branch retinal vein occlusion (BRVO) cases, leading to visual loss in most of these cases. Intravitreal injection of anti-vascular endothelial growth factor is currently the standard treatment for macular edema due to BRVO (BRVO-ME). The differ...
Autores principales: | Kishishita, Shuta, Sakanishi, Yoshihito, Morita, Shu, Matsuzawa, Moe, Usui-Ouchi, Ayumi, Ebihara, Nobuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710148/ https://www.ncbi.nlm.nih.gov/pubmed/36447155 http://dx.doi.org/10.1186/s12886-022-02685-4 |
Ejemplares similares
-
Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
por: Sakanishi, Yoshihito, et al.
Publicado: (2017) -
Subfoveal Choroidal Thickness and Treatment Outcomes of Intravitreal Aflibercept for Branch Retinal Vein Occlusion
por: Sakanishi, Yoshihito, et al.
Publicado: (2021) -
Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
por: Sakanishi, Yoshihito, et al.
Publicado: (2016) -
Seasonal variation in the occurrence of retinal vein occlusion: a 4-year cross-sectional study
por: Matsuzawa, Moe, et al.
Publicado: (2020) -
Comment on: Ranibizumab and aflibercept intravitreal injection for treatment
naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)